Recreating Winchendon Village: A Distinct Destination in Toy Town (Winchendon, MA)

The goal of the Master of Regional Planning Studio is to develop a student’s techniques for collecting, analyzing, and synthesizing spatial and non-spatial data and then presenting that collective data in a manner (i.e., report, video, presentation, and charettes) that is understandable to academics, professionals, and the public. Planning Studio allows students to integrate knowledge from coursework and research, and apply such knowledge to resolving representative planning problems. At UMASS Amherst, these problems are found in neighborhood, rural, urban, and/or regional settings. In the fall of 2014, three local governments contracted with the MRP Studio to create separate vision plans that focused on key aspects of community revitalization. For the Town of Winchendon, the graduate student team (Carousel Consulting) created a revitalization plan that addressed declining investment and commercial activity in the Central Street corridor. As the “downtown” and commercial center of Winchendon, the strategy for Central Street focused on generating reinvestment through the advancement of commercial development and diversity, infill development and cohesion, place-making and branding, open space and recreation, and circulatory functionality

Commonwealth of Massachusetts Mill Building Repurposing Pilot Project (Twist Mill - Athol, MA)

The purpose of the UMass Amherst Department of Landscape Architecture and Regional Planning’s participation in this project is to establish a redevelopment action plan that incorporates the ownership’s clear vision for reuse of the site, proposes solutions to various obstacles that have hindered progress, and serves as a guiding model in terms of improving the feasibility of similar projects throughout the state. The project team gathered information from a variety of resources, and conducted three distinct phases of analysis in order to complete this redevelopment action plan. The Phase I: Inventory examines the physical, regulatory, and financial context surrounding the current site in order to gauge its condition as a viable location to foster desired economic development for the region. The Phase II: Assessment utilizes these inventory findings to identify clear challenges that impact the redevelopment potential of the site in an effort to reduce overall project roadblocks. The Phase III: Implementation provides strategies to alleviate these challenges moving forward, in the form of clear recommendations for local, regional, and state level regulatory improvements. Phases I and II were conducted in the fall of 2013, and Phase III was conducted in the spring of 2014. Particular thanks for guidance on this project are extended to L.P. Athol Corporation ownership, Dr. John Mullin of the UMass Amherst Center for Economic Development, State Representative Denise Andrews of the Franklin County Second District, State Senator Stephen Brewer, State Senator Stanley Rosenberg, Congressman James McGovern, and the Town of Athol

TOI-836 : a super-Earth and mini-Neptune transiting a nearby K-dwarf

Funding: TGW, ACC, and KH acknowledge support from STFC consolidated grant numbers ST/R000824/1 and ST/V000861/1, and UKSA grant ST/R003203/1.We present the discovery of two exoplanets transiting TOI-836 (TIC 440887364) using data from TESS Sector 11 and Sector 38. TOI-836 is a bright (T = 8.5 mag), high proper motion (∼200 mas yr−1), low metallicity ([Fe/H]≈−0.28) K-dwarf with a mass of 0.68 ± 0.05 M⊙ and a radius of 0.67 ± 0.01 R⊙. We obtain photometric follow-up observations with a variety of facilities, and we use these data-sets to determine that the inner planet, TOI-836 b, is a 1.70 ± 0.07 R⊕ super-Earth in a 3.82 day orbit, placing it directly within the so-called ‘radius valley’. The outer planet, TOI-836 c, is a 2.59 ± 0.09 R⊕ mini-Neptune in an 8.60 day orbit. Radial velocity measurements reveal that TOI-836 b has a mass of 4.5 ± 0.9 M⊕, while TOI-836 c has a mass of 9.6 ± 2.6 M⊕. Photometric observations show Transit Timing Variations (TTVs) on the order of 20 minutes for TOI-836 c, although there are no detectable TTVs for TOI-836 b. The TTVs of planet TOI-836 c may be caused by an undetected exterior planet.Publisher PDFPeer reviewe

TOI-836: A super-Earth and mini-Neptune transiting a nearby K-dwarf

We present the discovery of two exoplanets transiting TOI-836 (TIC 440887364) using data from TESS Sector 11 and Sector 38. TOI-836 is a bright ($T = 8.5$ mag), high proper motion ($\sim\,200$ mas yr$^{-1}$), low metallicity ([Fe/H]$\approx\,-0.28$) K-dwarf with a mass of $0.68\pm0.05$ M$_{\odot}$ and a radius of $0.67\pm0.01$ R$_{\odot}$. We obtain photometric follow-up observations with a variety of facilities, and we use these data-sets to determine that the inner planet, TOI-836 b, is a $1.70\pm0.07$ R$_{\oplus}$ super-Earth in a 3.82 day orbit, placing it directly within the so-called 'radius valley'. The outer planet, TOI-836 c, is a $2.59\pm0.09$ R$_{\oplus}$ mini-Neptune in an 8.60 day orbit. Radial velocity measurements reveal that TOI-836 b has a mass of $4.5\pm0.9$ M$_{\oplus}$ , while TOI-836 c has a mass of $9.6\pm2.6$ M$_{\oplus}$. Photometric observations show Transit Timing Variations (TTVs) on the order of 20 minutes for TOI-836 c, although there are no detectable TTVs for TOI-836 b. The TTVs of planet TOI-836 c may be caused by an undetected exterior planet

TOI-836: A super-Earth and mini-Neptune transiting a nearby K-dwarf

peer reviewe

A close-in puffy Neptune with hidden friends : the enigma of TOI 620

We present the validation of a transiting low-density exoplanet orbiting the M2.5 dwarf TOI 620 discovered by the NASA Transiting Exoplanet Survey Satellite (TESS) mission. We utilize photometric data from both TESS and ground-based follow-up observations to validate the ephemerides of the 5.09 day transiting signal and vet false-positive scenarios. High-contrast imaging data are used to resolve the stellar host and exclude stellar companions at separations ≳0farcs2. We obtain follow-up spectroscopy and corresponding precise radial velocities (RVs) with multiple precision radial velocity (PRV) spectrographs to confirm the planetary nature of the transiting exoplanet. We calculate a 5σ upper limit of MP < 7.1 M⊕ and ρP < 0.74 g cm−3, and we identify a nontransiting 17.7 day candidate. We also find evidence for a substellar (1–20 MJ) companion with a projected separation ≲20 au from a combined analysis of Gaia, adaptive optics imaging, and RVs. With the discovery of this outer companion, we carry out a detailed exploration of the possibilities that TOI 620 b might instead be a circum-secondary planet or a pair of eclipsing binary stars orbiting the host in a hierarchical triple system. We find, under scrutiny, that we can exclude both of these scenarios from the multiwavelength transit photometry, thus validating TOI 620 b as a low-density exoplanet transiting the central star in this system. The low density of TOI 620 b makes it one of the most amenable exoplanets for atmospheric characterization, such as with the James Webb Space Telescope and Ariel, validated or confirmed by the TESS mission to date

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

IMPORTANCE Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes